Salarius Pharma falls on ending early-stage bone cancer study

Decoy Therapeutics

19/07/2024 22:46

** Shares of drug developer Salarius Pharmaceuticals
 SLRX.O  fall 4.4% to $1.75 after the bell  
    ** Co to close its ongoing early-stage trial testing its
experimental drug seclidemstat in patients with a type of bone
cancer
    ** Co says it is ending the study in an effort to conserve
cash while its board of directors continues its exploration of
potential strategic alternatives
    ** The US FDA placed a partial clinical hold on another
cancer study testing seclidemstat in patients with a type of
blood cancer on July 11 
    ** Up to last close, stock down 64.8% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))